Short communication: timeline of radiation-induced kidney function loss after stereotactic ablative body radiotherapy of renal cell carcinoma as evaluated by serial 99mTc-DMSA SPECT/CT

Radiation Oncology

Shankar Siva²  Tomas Kron⁴  Jason Callahan¹  Nicholas Hardcastle⁵  Michael S Hofman¹  Daniel Pham³  Farshad Foroudi²  Price Jackson⁴ 

[1] Department of Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia;Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia;Department of Radiotherapy, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia;Department of Physical Sciences, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia;Centre for Medical Radiation Physics, University of Wollongong, Wollongong, NSW, Australia

关键词: Single photon emission tomography;    Functional imaging;    Primary kidney cancer;    Renal cell carcinoma;    Stereotactic radiation;   

Others  :  1150863
DOI  :  10.1186/s13014-014-0253-z

 received in 2014-06-06, accepted in 2014-11-05,  发布年份 2014

【 摘 要 】

Background

Stereotactic ablative body radiotherapy (SABR) has been proposed as a definitive treatment for patients with inoperable primary renal cell carcinoma. However, there is little documentation detailing the radiobiological effects of hypofractionated radiation on healthy renal tissue.

Findings

In this study we describe a methodology for assessment of regional change in renal function in response to single fraction SABR of 26 Gy. In a patient with a solitary kidney, detailed follow-up of kidney function post-treatment was determined through 3-dimensional SPECT/CT imaging and ⁵¹Cr-EDTA measurements. Based on measurements of glomerular filtration rate, renal function declined rapidly by 34% at 3 months, plateaued at 43% loss at 12 months, with minimal further decrease to 49% of baseline by 18 months.

Conclusions

The pattern of renal functional change in ^99mTc-DMSA uptake on SPECT/CT imaging correlates with dose delivered. This study demonstrates a dose effect relationship of SABR with loss of kidney function.

【 授权许可】

   
2014 Jackson et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 2.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Walsh L, Stanfield JL, Cho LC, C-h C, Forster K, Kabbani W, Cadeddu JA, Hsieh J-T, Choy H, Timmerman R, Lotan Y: Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model. Eur Urol 2006, 50:795-800.
• [2]Ponsky LE, Crownover RL, Rosen MJ, Rodebaugh RF, Castilla EA, Brainard J, Cherullo EE, Novick AC: Initial evaluation of cyberknife technology for extracorporeal renal tissue ablation. Urology 2003, 61:498-501.
• [3]Siva S, Pham D, Gill S, Corcoran NM, Foroudi F: A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. BJU Int 2012, 110:E737-E743.
• [4]Wersäll PJ, Blomgren H, Lax I, Kälkner K-M, Linder C, Lundell G, Nilsson B, Nilsson S, Näslund I, Pisa P, Svedman C: Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol 2005, 77:88-95.
• [5]Wersäll PJ, Blomgren H, Pisa P, Lax I, Kälkner K-M, Svedman C: Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol 2006, 45:493-497.
• [6]Teh B, Bloch C, Galli-Guevara M, Doh L, Richardson S, Chiang S, Yeh P, Gonzalez M, Lunn W, Marco R, Jac J, Paulino A, Lu H, Butler E, Amato R: The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT). Biomed Imaging Interv J 2007, 3:e6.
• [7]Nomiya T, Tsuji H, Hirasawa N, Kato H, Kamada T, Mizoe J, Kishi H, Kamura K, Wada H, Nemoto K, Tsujii H: Carbon ion radiation therapy for primary renal cell carcinoma: initial clinical experience. Int J Radiat Oncol Biol Phys 2008, 72:828-833.
• [8]Svedman C, Karlsson K, Rutkowska E, Sandström P, Blomgren H, Lax I, Wersäll P: Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol 2008, 47:1578-1583.
• [9]Svedman C, Sandström P, Pisa P, Blomgren H, Lax I, Kälkner K-M, Nilsson S, Wersäll P: A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol 2006, 45:870-875.
• [10]Hartke D, Ponsky L: Renal radiosurgery. In New Technologies in Urology. Volume 7. Edited by Dasgupta P, Fitzpatrick J, Kirby R, Gill I. Springer, London; 2010:155-159. [New Techniques in Surgery Series]
• [11]Song CW, Cho LC, Yuan J, Dusenbery KE, Griffin RJ, Levitt SH: Radiobiology of stereotactic body radiation therapy/stereotactic radiosurgery and the linear-quadratic model. Int J Radiat Oncol Biol Phys 2013, 87:18-19.
• [12]Dawson LA, Kavanagh BD, Paulino AC, Das SK, Miften M, Li XA, Pan C, Ten Haken RK, Schultheiss TE: Radiation-associated kidney injury. Int J Radiat Oncol Biol Phys 2010, 76:S108-S115.
• [13]Lo SS, Sahgal A, Chang EL, Mayr NA, Teh BS, Huang Z, Schefter TE, Yao M, Machtay M, Slotman BJ, Timmerman RD: Serious complications associated with stereotactic ablative radiotherapy and strategies to mitigate the risk. Clin Oncol 2013, 25:378-387.
• [14]Pham D, Thompson A, Kron T, Foroudi F, Kolsky MS, Devereux T, Lim A, Siva S: Stereotactic ablative body radiation therapy for primary kidney cancer: a 3-dimensional conformal technique associated with low rates of early toxicity. Int J Radiat Oncol Biol Phys ᅟ, ᅟ:ᅟ. Advanced online publication. doi:10.1016/j.ijrobp.2014.07.043.
• [15]Pham D, Kron T, Foroudi F, Siva S: Effect of different breathing patterns in the same patient on stereotactic ablative body radiotherapy dosimetry for primary renal cell carcinoma: a case study. Med Dosim 2013, 38:304-308.
• [16]Morgan-Fletcher SL: Prescribing, recording and reporting photon beam therapy (Supplement to ICRU Report 50), ICRU Report 62. ICRU, pp. ix+52, 1999 (ICRU Bethesda, MD) $65.00 ISBN 0-913394-61-0. Br J Radiol 2001, 74:294-294.
• [17]Demirjian S, Lane BR, Derweesh IH, Takagi T, Fergany A, Campbell SC: Chronic kidney disease due to surgical removal of nephrons: relative rates of progression and survival. J Urol 2014, 192:1057-1063.